By Julia Evangelou Strait
The new drug sotorasib reduces tumor size and shows promise in improving survival among people with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial. The drug is designed to shut down the effects of the mutation, which is found in about 13% of people with lung adenocarcinoma, a common type of non-small-cell lung cancer. Non-small-cell lung cancer makes up over 80% of all lung cancers. And more than 200,000 new cases of non-small-cell lung cancer are diagnosed annually in the United States.
Read More